Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TGFBR2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TGFBR2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TGFBR2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TGFBR2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TGFBR2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TGFBR2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TGFBR2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00605608 | Prostate | BPH | developmental growth involved in morphogenesis | 58/3107 | 234/18723 | 8.28e-04 | 5.40e-03 | 58 |
GO:200037710 | Prostate | BPH | regulation of reactive oxygen species metabolic process | 42/3107 | 157/18723 | 8.41e-04 | 5.46e-03 | 42 |
GO:200037910 | Prostate | BPH | positive regulation of reactive oxygen species metabolic process | 24/3107 | 76/18723 | 9.29e-04 | 5.91e-03 | 24 |
GO:190303710 | Prostate | BPH | regulation of leukocyte cell-cell adhesion | 78/3107 | 336/18723 | 9.95e-04 | 6.25e-03 | 78 |
GO:001593110 | Prostate | BPH | nucleobase-containing compound transport | 55/3107 | 222/18723 | 1.12e-03 | 6.97e-03 | 55 |
GO:00486595 | Prostate | BPH | smooth muscle cell proliferation | 47/3107 | 184/18723 | 1.26e-03 | 7.62e-03 | 47 |
GO:005086310 | Prostate | BPH | regulation of T cell activation | 76/3107 | 329/18723 | 1.32e-03 | 7.95e-03 | 76 |
GO:00487543 | Prostate | BPH | branching morphogenesis of an epithelial tube | 40/3107 | 151/18723 | 1.35e-03 | 8.10e-03 | 40 |
GO:0003231 | Prostate | BPH | cardiac ventricle development | 34/3107 | 123/18723 | 1.37e-03 | 8.20e-03 | 34 |
GO:002240915 | Prostate | BPH | positive regulation of cell-cell adhesion | 67/3107 | 284/18723 | 1.41e-03 | 8.40e-03 | 67 |
GO:00605415 | Prostate | BPH | respiratory system development | 50/3107 | 203/18723 | 2.09e-03 | 1.17e-02 | 50 |
GO:0035162 | Prostate | BPH | embryonic hemopoiesis | 10/3107 | 23/18723 | 2.20e-03 | 1.22e-02 | 10 |
GO:00032792 | Prostate | BPH | cardiac septum development | 29/3107 | 103/18723 | 2.20e-03 | 1.22e-02 | 29 |
GO:0010717 | Prostate | BPH | regulation of epithelial to mesenchymal transition | 28/3107 | 99/18723 | 2.42e-03 | 1.31e-02 | 28 |
GO:00466343 | Prostate | BPH | regulation of alpha-beta T cell activation | 29/3107 | 104/18723 | 2.58e-03 | 1.38e-02 | 29 |
GO:00466313 | Prostate | BPH | alpha-beta T cell activation | 40/3107 | 156/18723 | 2.58e-03 | 1.38e-02 | 40 |
GO:00603483 | Prostate | BPH | bone development | 50/3107 | 205/18723 | 2.60e-03 | 1.39e-02 | 50 |
GO:00032052 | Prostate | BPH | cardiac chamber development | 41/3107 | 161/18723 | 2.63e-03 | 1.41e-02 | 41 |
GO:19013424 | Prostate | BPH | regulation of vasculature development | 78/3107 | 348/18723 | 2.76e-03 | 1.46e-02 | 78 |
GO:00300982 | Prostate | BPH | lymphocyte differentiation | 83/3107 | 374/18723 | 2.76e-03 | 1.46e-02 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGFBR2 | SNV | Missense_Mutation | | c.1528G>A | p.Glu510Lys | p.E510K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
TGFBR2 | SNV | Missense_Mutation | | c.382G>A | p.Asp128Asn | p.D128N | P37173 | protein_coding | tolerated(0.83) | benign(0.061) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
TGFBR2 | SNV | Missense_Mutation | novel | c.673A>G | p.Thr225Ala | p.T225A | P37173 | protein_coding | tolerated(0.89) | benign(0) | TCGA-LL-A50Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1559N>A | p.Arg520Gln | p.R520Q | P37173 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
TGFBR2 | insertion | Nonsense_Mutation | novel | c.939_940insTTGCAGTGAGCAGAGATCGTGCCATTGCACTGCTGCCTGGGTA | p.Thr314LeufsTer3 | p.T314Lfs*3 | P37173 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | novel | c.116A>C | p.Lys39Thr | p.K39T | P37173 | protein_coding | tolerated_low_confidence(0.15) | benign(0.026) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs886039551 | c.1411N>A | p.Asp471Asn | p.D471N | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1664N>T | p.Thr555Ile | p.T555I | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | | c.1393G>A | p.Glu465Lys | p.E465K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs104893809 | c.1684C>T | p.Arg562Cys | p.R562C | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 178101755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TGF-BR2 mab | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TG-C | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565835 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 348353672 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | irinotecan | IRINOTECAN | 27160286 |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565874 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 223366128 | GALUNISERTIB | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565800 | | |